Your browser doesn't support javascript.
loading
Single-stranded RNA adjuvant enhances the efficacy of 10-valent human papilloma virus-like particle vaccine.
Kwak, Hye Won; Shin, Wooseok; Baik, Kyunghwa; Kim, Minsun; Park, YongWook; Hong, So-Hee; Park, Hyo-Jung; Park, Hyeong-Jun; Bang, Yoo-Jin; Kim, Jae-Yong; Lee, Yu-Sun; Kim, In-Beom; Kim, Hong-Lim; Kim, Hun; Nam, Jae-Hwan.
Affiliation
  • Kwak HW; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
  • Shin W; Department of R&D, SMLbiopharm, Bucheon, Republic of Korea.
  • Baik K; BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.
  • Kim M; Department of R&D, SK Bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Park Y; Department of R&D, SK Bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Hong SH; Department of R&D, SK Bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Park HJ; Department of R&D, SK Bioscience, Pangyoro, Bundang-gu, Republic of Korea.
  • Park HJ; Department of Microbiology, College of Medicine, Ewha Womans University, Seoul, Republic of Korea.
  • Bang YJ; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
  • Kim JY; BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.
  • Lee YS; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
  • Kim IB; Department of R&D, SMLbiopharm, Bucheon, Republic of Korea.
  • Kim HL; BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.
  • Kim H; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
  • Nam JH; Department of R&D, SMLbiopharm, Bucheon, Republic of Korea.
Microbiol Immunol ; 66(11): 529-537, 2022 Nov.
Article in En | MEDLINE | ID: mdl-35979884
ABSTRACT
Following the development of various types of vaccines, the use of adjuvants to boost vaccine efficacy has become a focus of research. Aluminum hydroxide (alum), the most commonly used adjuvant, induces a certain immune response and ensures safety in human trials. However, alum mainly induces only a Th2 response; its Th1 response is weak. Thus, we previously developed a single-stranded ribose nucleic acid (ssRNA) adjuvant that induces a Th1 response through toll-like receptors. Here, we explored whether 10-valent human papilloma virus (HPV)-like particle (VLP) vaccine formulated with ssRNA adjuvant and alum helped to enhance immune response and maintained memory response. The mice were immunized intramuscularly twice at 2 week intervals and were inoculated 4 days after the second boost (after about 1 year). The antibody response and T cell activation were measured by Elispot, ELISA using harvested serum and splenocytes. The 10-valent HPV VLP vaccine formulated with ssRNA adjuvant and alum increased the antigen-specific immune response more than alum used alone. It increased each type-specific IgG1/IgG2a titer, and antigen-specific IFN-γ cells. Furthermore, the ssRNA adjuvant with alum induced memory response. In memory response, each type-specific IgG1/IgG2c, IFN-γ, and IL-6 cytokine, and neutralizing antibodies were increased by the ssRNA adjuvant with alum. Overall, the ssRNA adjuvant with alum induced memory responses and balanced Th1/Th2 responses. The ssRNA adjuvant and alum may help to enhance prophylactic vaccine efficacy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Papilloma / Papillomavirus Infections / Alphapapillomavirus / Papillomavirus Vaccines / Vaccines, Virus-Like Particle Limits: Animals / Humans Language: En Journal: Microbiol Immunol Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Papilloma / Papillomavirus Infections / Alphapapillomavirus / Papillomavirus Vaccines / Vaccines, Virus-Like Particle Limits: Animals / Humans Language: En Journal: Microbiol Immunol Year: 2022 Document type: Article